BioHealth News
STEMCELL Technologies Announces Acquisition of Gaithersburg’s Propagenix Inc.
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing…
Read More
Genetic Engineering & Biotechnology News: AI in Drug Discovery: Trust, but Verify
Tiffany Yesavage, PhD - January 11, 2024 - The use of artificial intelligence (AI) to develop new drugs is in its infancy. Nevertheless, AI-designed drugs have…
Read More
Virginia Catalyst Announces Grant Round 15 Awarded Projects
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to…
Read More
BioHealth Innovation, Inc.’s Rich Bendis Named Finalist for the Community Builder Award in the 2023 BioHealth Capital Region Annual Awards
Rockville, MD – BioHealth Innovation, Inc. (BHI) is proud to announce that our Founder, President & CEO, Rich Bendis, has been named a finalist…
Read More
Luminoah’s Receives $463,000 Grant from Virginia Catalyst
CHARLOTTESVILLE, VA – January 11, 2024 – Luminoah Inc., a medical technology company dedicated to improving the standard of care for patients requiring enteral nutrition,…
Read More
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase II AAVIATE® trial of ABBV-RGX-314…
Read More
BioHealth Innovation, Inc. (BHI) Welcomes Peter Ronco as a New Member of the Board of Directors
ROCKVILLE, MARYLAND, January 16, 2024– BioHealth Innovation, Inc. (BHI), a leading public-private non-profit organization dedicated to advancing healthcare innovation in the BioHealth Capital Region,…
Read More
Children’s National Novel AI platform matches cardiologists in detecting rheumatic heart disease
WASHINGTON, D.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) has the potential to detect rheumatic heart disease (RHD) with the same accuracy…
Read More
BioHealth Innovation Insights from the 2024 J.P. Morgan Healthcare Conference
BioHealth Innovation (BHI) was prominently represented at the 2024 J.P. Morgan Healthcare Conference, with several Entrepreneurs-in-Residence (EIRs) in attendance. The insights gathered by…
Read More
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
GERMANTOWN, Md., Jan. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies…
Read More
Rockville’s NeoImmuneTech Welcomes a New President for its Development and Business
ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D.,…
Read More
Bio.News: With the new COVID surge, are we really post-pandemic?
January 9, 2024 / By Clary Estes - National wastewater viral activity levels for COVID-19 have been very high since December. (It wasn’t your imagination that everyone seemed sick over…
Read More
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value…
Read More
GSK Enters Agreement to Acquire Aiolos Bio
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway AIO-001 could redefine the standard-of-care with…
Read More
KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors
KeifeRx is currently advancing programs investigating KFRX03, KFRX04, KFXR05 and KFX06 in neurodegenerative, neuroinflammatory, and mast cell-associated diseases WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- KeifeRx, an…
Read More